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Development and validation of stability indicating HPLC method for drug stability studies
Hana Chlubnová
Drugs represent preparations with long shelf-life. From this reason it is necessary to have 
substances chemically and physically stable and prevent possible degradation or forming 
complexes during whole shelf-life.
We need to check the stability of preparations. One of the appropriate methods is using of 
HPLC having several  advantages  e.g.  in  simlipicity and availability.  Before  measuring 
there is a requirement to determinate proper conditions and validate the chosen method.
In  the  experimental  part  of  this  thesis  there  are  stated  conditions  and  results  of  38 
measured substances. Based on the results it  was chosen one suitable method that was 
validated  for  10  concrete  active  substances.  There  are  results  of  stability  of  these 
substances after melt-quenching in the last part. 
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Abstrakt
Univerzita Karlova v Praze
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Katedra farmaceutické technologie
Vývoj a validace HPLC metody pro stabilitní studie léčiv
Hana Chlubnová
Léky představují přípravky s dlouhou dobou použitelnosti. Z tohoto důvodu je potřeba, aby 
látky byly chemicky a fyzikálně stabilní a zabránit tak možnému rozkladu nebo tvorbě 
komplexů v průběhu celé doby použitelnosti.
Potřebujeme kontrolovat stabilitu přípravků. Jedna z vhodným metod je použití HPLC, 
které má několik výhod např. jednoduchost a dostupnost. Před měřením je potřeba stanovit 
vhodné podmínky a validovat vybranou metodu.
V experimentální části této práce jsou uvedeny podmínky a výsledky 38 měřeným látek. 
Na základě těchto výsledků byla vybrána vhodná metoda, která byla validována pro 10 












HPLC......................high pressure liquid chromatography
Mr............................molecular weight
NSAIDs..................non-steroidal antiinflammatory drugs
pH...........................a measure of the acidity or basicity of an aqueous solution 
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Goal of the thesis
The  goal  of  the  theoretical  part  is  to  describe  amorphous  solids,  their  properties  and 
preparation in short way then characterize chemical and physical degradation and show 
possible techniques to improve stability.
The  subject  of  experimental  part  was  to  determinate  possible  degradation  of  several 
samples  that  were  modified  by  melt-quenching.  For  this  purpose  we  developed  and 
validated an HPLC method that gave us valid results of stability measured compounds.
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1. Theoretical part
Active substances used in pharmacetical industry and more other areas are mostly in solid 
state.  They can  exist  in  many forms  such  as  amorphous  solids,  crystals,  polymorphs, 
hydrates,  solvates.  They  have  different  chemical,  physical,  thermal  and   mechanical 
properties  that  lead  to  a  turn  in  other  characteristics  (melting  point,  bioavailibility, 
stability).  Transitions  between  the  forms  result  in  possible  clinical  and  toxicological 
changes. Scientists have to develop various methods to prevent these changes and find new 
drug delivery systems to guarantee safety, effectiveness and quality during whole shelf-
life.
1. 1 Amorphous Solids
1. 1. 1 Solid states
Crystalline state (1)
It is a solid with a short and a long-range order with atoms or molecules in a fixed lattice 
arrangement. The main difference between crystalline and amorphous state is in their long-
range order.  Due to  its  arrangements  it  is  accessible  to  use  X-ray diffraction  analysis. 
Crystal morphology (2) is general appearance of the faces that show and give the crystals 
their characteric shape. The habit is the general shape as given by relative length of the 
major axes. These two characteristics depend on surrounding conditions. Crystals exist in 
seven systems (cubic, tetragonal, orthorhombic, monoclobic, triclinic, trigonal, hexanol). 
Their dividing is based on single side lengths and angles. 
The crystalline state is usually more thermodynamically stable than amorphous one.
Amorphous state (3, 4)
For amorphous state it is sometimes used term glass as a synonymum. Glass is a physical 
state undergoing through a melt quenching or a glass transition. The term amorphous state 
can be used in general indefinite way.
It  is  a  solid  with  a  short-range molecular  order  and no long-range order  of  molecular 
packing or well-defined molecular conformation. They may posses residual crystalinity, 
polymorphic states. They can be characterized as the frozen solids and the cooled viscous 
liquid because of their random arranging of molecules.  Because of the structure it is not 
possible to use X-ray diffraction.
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Figure  1.  Structural  comparing  of  one  compound  (SIO2)  in  crystalline  and 
amorphous state (5)
     
Polymorphism (2, 3)
It is the ability of a solid material to have more than one possible crystal form. They can be 
different in physical and chemical properties and their transfer may have an influence on 
characteristics  of  final  product.  There  exist  several  types  of  polymorphism;  packing 
polymorphism  (packing  and  bonding  arrangement  in  different  forms  are  different, 
conformational polymorphism, pseudopolymorphism (a new structure that is hydrated or 
solvated)
1. 1. 2 Amorphous solids; properties and preparation
Amorphous solids are used in many area of interest thanks to their properties. They are in 
polymers, ceramics,  optical materials  (glasses,  fibers),  foods,  and also pharmaceuticals. 
They are  the  common  form of  certain  materials  (proteins,  peptides,  some  sugars  and 
polymers).  The  current  interest  has  been  elevated  by  two  developments:  a  growing 
attention  to  pharmaceutical  solids  in  general  (especially  polymorphs  and  solvates),  a 
revived interest in the science of glass and the glass transition. (3)
Properties of amorphous solids
The amorphous solid properties are different from crystal  form of the same substance. 
They are regulated by temperature.
Amorphous  solids  have  higher  solubilty,  dissolution  rate,  and  sometimes  better 
compression characteristics than corresponding crystals. They are generally more unstable 
physically  and  chemically.  They  have  higher  energy,  entropy  and  free  energy  than 
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corresponding crystals. (3)
Important characteristic is the glass transition temperature (Tg). The glass transition (6) is a 
reversible process  when the amorphous, hard, glass like state goes to a rubber like state. 
Tg  is a exact temperature where it is happenning. It is a kinetic parameter depending on 
temperature  scanning rate,  thermal  history,  and useful  material  descriptor.  It  is  always 
lower  than  the  melting  temperature  (Tm)  of  the  crystalline  state.  Differential  scanning 
calorimetry (DSC)  can  measure  rate  of  possible  crystallization  and amount  of  present 
water that may have an influance on its stability and properties. DSC defines the glass 
transition as a change in the heat capacity as the amorphous solis goes from the glass state 
to the rubber state.
Preparation
We have two groups of materials good glass formers, where the preparation of amourphous 
solids is easy, and poor glass formers, where it is difficult. 
We have several routes to prepare amorphous solids that include melt quenching, freeze-
drying,  spray-drying,  rapid  precipitation  by  addition  of  antisolvents,  intruduction 
impurities, and solid dispersion.(3)
Melt quenching is not technique largely used for production of pharmaceutical products 
but it is very valuable in laboratory scale to prepare the amorphous state of compound. 
Solids are heated above the melting point and rapidly cooled down, typically by pouring 
into liquid nitrogen, to prevent a nucleation and growth. The amorphous form is trapped 
due  to  the  continuously  increasing  viscosity  of  the  rapidly  cooling  melt.  In  contrast, 
crystallization of melt occurs with an abrupt change in viscosity, during which crystallites 
grow in the body of the melt.(4)
Freeze-drying is a process for prepartion of stable material but can be rebuild by using 
water. It also used in food industry.
Spray-drying (7) is a technique to get amourphous solids by drying rapidly from solution. 
It  must  be  done  quickly  to  prevent  possible  recrystallize.  Present  of  water  leads  to 
crystallize , so the amourphous solids must be kept in dry conditions.
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1. 2 Drug Stability (8, 9, 10)
It is defined as capacity of a drug substance or drug product remaining in the specifications 
to  maintain  its  identity,  strength,  quality  and  purity  throughout  the  shelf-life.  It  is  an 
important  factor  of  safety,  efficacy and quality  of  the  product  drug.  If  there  is  not  of 
sufficient stability some changes in physical or chemical characteristics can happen. In the 
first  case the drug can degrade to  toxic derivatives,  in the second case  the drug may 
become   esthetically unacceptable and in the last one it must be achieved that the oral 
formulation   is  enough  stable  under  the  pH  conditions  which  are  found  in  the 
gastrointestinal track.                                          
The pharmaceutical products usually have a shelf-life of 3 years.  During these years the 
potency should not decrease below 95%  in the recommended conditions.  The product 
should look and perform in the same way as the first time. The most common constant how 
to describe stability is the half-life. It is time at which the concentration has halved (t 1/2 or 
t50).  For the shelf-life it is expressed as t95 which means the time for 5% loss.     
1. 2. 1 Chemical degradation (8)
There  are  several  factors  and  conditions  affecting  chemical  stability.  Firstly  it  is  a 
molecular  structure  of  the  drug.  Other  ones  are  temperature,  pH,  buffer  species,  ionic 
strength, light, oxygen, moisture, additives, and excipients.
Chemical  drug  degradation  can  be  divided  into  five  main  groups  as  hydrolysis, 
dehydration,  oxidation,  isomerization  and  racemization,  elimination,  photolysis  and 
complex interactions with excipients and other drug. Hydrolysis and oxidation are the most 
common pathways and then the photolysis.
Hydrolysis
It is the most likely cause of drug instability.  We have two groups of solvents which can 
cause the hydrolysis. The first is water, it has a dominant role in dissolving. The second one 
is non-water solvent. In this case this process is called solvolysis.
Hydrolytic  reactions  involve  nucleophilic  attack  of  labile  bonds,  e.g.  lactam > ester  > 
amide > imide.   There is  number of conditions which can catalyse the breakdown: the 
presence of H3O+, OH-, divalent ions, when ionic hydrolysis is faster than molecular, and 
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also heat, light, solution polarity and ionic strength and high drug concentration.
Many drugs are the most stable in range of pH 4 and 8. The extremes of pH can catalysed 
the degradation of the drugs.  This is monitored by measuring degradation rates against pH, 
keeping, ionic strength, solvent concentration and temperature constant. We can also use 
acetate, lactate, phosphate, citrate or ascorbate buffers. Many drugs are unfortunately weak 
acids or basis. They have to be ionized for dissolution but it leads to more instability. It can 
be solve, in some cases, by addition a water-miscible solvent in the formulation. 
Solvolysis is the term for breakdown when the reacting solvent is not water. This effect is 
connected with the polarity of the solvent. If a compound produces degradation products 
which are more polar then the addition of a less polar solvent will stabilize the formulation. 
If the degradation products are less polar, then the vehicle should be more polar to improve 
stability.                                                     
Dehydration
The dehydration is a chemical reaction that involves the loss of the water from the reacting 
molecule. Because the hydroxyl group (-OH) is a poor leaving group, having an Brønsted 
acid catalyst often helps by protonating the hydroxyl group to give the better leaving group, 
-OH2+.  For  example  glucose  and  lactose  undergo  degradation  to  form  5-
(hydroxymethyl)furural.
Oxidation
It  is  a  loss  of  electrons  and the  oxidizing  agent  has  to  be  able  to  take  electrons.  The 
reduction is the reverse reaction and there is a mutual exchange of electrons.  Oxidation is 
called dehydrogenation in organic chemistry.   The mechanism depends on the chemical 
structures of the drugs and the presence of reactive oxygen species or other oxidants. We 
can protect the drug by addition of antioxidants. For their successful it is necessary to use 
antioxidants which are more readily oxidized than the drug.
Isomerization and racemization 
Isomerisation is the process by which one molecule is transformed into another molecule 
which has exactly the same atoms, but the atoms changed their places. Racemization is a 
partial conversion of one  enantiomer into another. One of the most known examples of 
isomerisation are trans-cis isomerism,  ketoaldose isomerism
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Elimination
It  is  a chemical reaction where double bond is  created.   Atoms or group of atoms are 
eliminated from two neighboring carbon atoms. Between these two atoms double bond 
arises and so as a low molecular product. Dehydration is a subset of elimination. Other 
examples are decarboxylation, dehydrohalogenation. 
Photolysis
Oxidation and some hydrolysis can be catalyzed by light. Increasing of energy can lead to 
decomposition, converting to heat, it can result in light emission at a new wavelength or be 
retained or transferred (10)  We can protect drugs by using packaging into low actinic 
amber glass bottles, aluminium foil overwraps and blisters or cardboard outers.
Interactions with excipients and other drug
Quite often, reactions can occur between the drug and one or more additives. Similarly, two 
drugs might be formulated in the same product and react with each other. The example of 
these reacting drugs is reaction of amines with reducing sugars.
1. 2. 2 Physical degradation (8)
Drug substances together with excipients can exist in various microscopic physical states 
with different degrees of arrangement. Examples are amorphous and various crystalline, 
hydrated and solvated states. The components may change the state during the time from 
unstable to more stable. It all depends on chemical potential corresponding to the free-
energy difference between the states and the energy barriers that must be overcome for the 
conversion. 
Factors having an influence on physical degradation are the same as for chemical one, 
specifically plasticizing effect of water.
Crystallization of amorphous drugs
Drugs are often formulated as poorly water-soluble in their amorphous state. The ground is 
in their higher solubility in amorphous state than in their crystalline. However crystalline 
state  has  lower  free  energy  leading  to  change  of  amorphous  state  into  crystalline 
thermodynamically stable state within time. This may occur during long-term storage and 
can lead to many changes in their characteristics, clinical and toxicological behaviour.
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Transitions in crystalline state
Polymorphs are various crystalline phases of the same drugs. They are different in their 
free  energy and  chemical  potentials.  All  this  depends  on  surrounding  temperature  and 
humidity. During the storage change of solubility and dissolution may occur. Differences 
can also exist between the anhydrous and hydrated forms of the same drug.
Formation and growth of crystals
Crystals in molecules do not remain static. They  can increase, decrease, and travel across 
the medium which can be liquid or gaseous phase. The components may recrystallize or 
sublime onto the surface. This can be called “whisker” crystallization and may occur in 
porous tablets and at higher temperatures.
Vapor-phase transfer including sublimation
Also some components can sublime easily e.g. nitroglycerin. This was inhibited by using 
water-soluble fixing agents such as polyethylene glycol.
Moisture adsorption
This is mostly observed with solid pharmaceuticals. This can lead to changes in properties 
as appearance and dissolution rate.
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1. 3 Techniques to improve stability
We  have  several  techniques  how  to  improve  stability:  the  using  cyclodextrins  and 
formation  of  inclusion  complexes,  the  incorporation  into  emulsiones,  micelles  and 
liposomes,  the  addition  of  stabilizers,  the  modification  of  molecular  structure  and  the 
complex formation. (8) In following text I will focus more on cyclodextrins, liposomes, 
micelles, and emulsiones.
For some compounds it is necessary to arrange specific conditions during storing such as 
low temperature, no light and no access of oxygen. (8)   
1. 3. 1 Cyclodextrins and formation of inclusion complexes (8, 11, 12, 13)
They belong to the family of cyclic oligosaccharides with a hydrophylic outer surface and a 
lipophilic  central  cavity.  They  were  firstly  isolated  from  starch  in  1891  by  a  French 
scientist A. Villiers.  
They consist  of  (α-1,4)-linked  α-D-glucopyranose  unit.  They are  in  a  chair  formation 
causing shape like cones with secondary hydroxyl groups extending from the wider edge 
and the primary groups from the narrow edge. The naturally occurring cyclodextrins are α-
CD containing 6 glucopyranose units,  β-CD containing 7 units  and γ-CD containing 8 
units. They are displayed on the Figure 2. The real three-dimensional shape is displayed on 
the Figure 3. Except the naturally occurring CDs having quite low aqueous solubility there 
exist many CD derivatives resulting in dramatic improvement of their  aqueous solubility. 
Examples  of  derived  CDs:  2-Hydroxypropyl-β-cyclodextrin  (HPβCD),  Sulfonylether  β-
cyclodextrin sodium salt (SBEβCD), Randomly methylated β-cyclodestrin (RMβCD), 6-O-
Maltosyl-β-cyclodextrin (G2βCD), and 2-Hydroxypropyl-γ-cyclodextrin (HpγCD).  
Figure  2. Structural  representations  of  β-cyclodextrin,  α-cyclodextrin,  and  γ-
cyclodextrin (14) 
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Figure 3. The real toroid shape of  β-cyclodextrin (15)
      
Cyclodextrins have an ability to interact with poorly water-soluble drugs resulting in an 
increase in their apparent water solubility. The mechanism is based on formation of non-
covalent dynamic inclusion complexes in solution. They can also form non-inclusion based 
complexes, aggregates, and form and stabilize supersaturated drug solutions. They are used 
as a carrier delivery system in the form of inclusion complexes with drug molecules. That 
has several advantages. It can enhance aqueous solubility, stability and biovailability, it can 
be  used  for  prevention  of  incompatibility,  masking  of  unpleasant  taste  and  odour  and 
reduction of  irritation.
They are produced from starch by enzymatic conversion. There are used used two enzymes 
α-amylase  and  cyclodextrin  glycosyltransferase  (CGTase).  As  the  first  step  starch  is 
liquified  by  heating  or  using   α-amylase  then  CGTase  is  added  for  the  enzymatic 
conversion. It can synthesize all form of CDs. The product is a mixture in ratios depending 
on the enzyme used. The following purification is based on their water solubility. 
Methods used for preparation of CD inclusion complexes are grinding, solid dispersion/co-
evaporated  dispersion,  neutralization  method,  kneading  method,  precipitation  method, 
spray drying, freeze drying and melting (11)
CDs can be widely used. They are used in pharmacy in many delivery systems such as oral, 
parenteral, ocular, nasal, rectal, dermal and transdermal delivery, and mostly used for lipid-
soluble vitamins and hormones. They can be also used in food, and chemical industries, as 
well as agriculture and environmental engineering. 
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1. 3. 2 Incorporation into liposomes, micelles, and emulsiones
Liposomes (16, 17)
They are an artificially-prepared phospholipidic bilayer vesicles. Their size depends on the 
composition and preparation method. It is vary from 20 nm to 10μm. Thickness of bilayer 
membrane is 5nm. They can be divided into several groups according to to their structure 
and size.
SUV Small unilamellar vesicles 20 – 50nm
LUV Large unilamellar vesicles >50nm
OLV Oligolamellar vesicles 100nm – 1μm
MLV Multilamellar large vesicles 100nm – 10μm
MVV Multivesucullar vesicles 100nm – 10μm
They are composed of natural phospholipids and may also contain mixed lipids chains such 
as  phosphatidylcholin,  phosphatidylethanolamide,  phosphatidylserin  and 
phospatidylglycerol. The vesicle structures are displayed on the Figures 4a and 4b.
Figure 4a. Scheme of a liposome formed by phospholipids (18)
      
Figure 4b. Scheme of a liposome formed by phospholipids in three-dimension (19)
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There are several methods to prepare liposome. (16) The mostly used is lipid hydration 
method.  The  others  are  solvent  spherule  method,  sanitation  method,  solvent  injection 
method, microfluidization method and freeze-thaw method.
They  are  used  in  pharmacy  as  carriers  for  drug  molecules,  both  hydrophilic  and 
hydrophobic.  It  can  happened   in  three  ways:  encapsulation  of  hydrophilic  molecules, 
adsorption of ambiphilic molecules and incorporation of hydrophobic molecules into the 
bilayer. Their advantages are reduction of toxicity and increasing of effectiveness. They can 
be target to the concrete spot in a body. They can modulate speed of release. 
Liposomes  can  be  used  in  dermal  or  transdermal  preparations  and  in  injections 
(amfotericine B, daunorubicine).
Except pharmacy they are used in agriculture, food industry and cosmetics. 
Micelles (20)
They are aggregates of surfactant molecules dispersed in a liquid. They have the ability as 
surfactants to low the surface tension. They consist two different parts; hydrophilic head 
and  hydrophobic  tail.  In  aqueous  solution  they  form the  aggregate  where  the  head  is 
oriented to the solution and the tail oriented to the centre of micelle showed at the Figure 5. 
We recognize  two types of micelles – a normal phase micelle (o/w), and an inverse micelle 
(w/o). They can have various types of shapes – spherical, ellipsoids, cylinders, and bilayers. 
The side and shape depend on surrounding conditions such as surfactant concentration, pH, 
temperature,  and ionic strength.
Important characteristic is the critical micelle concentration (CMC). It is the concentration 
where above that the micelles can only form and also temperature has to be greater than 
critical micelle temperature.
They  are  used  as  emulsifiers  causing  a  compound,  normally  insoluble,  soluble.  In 
pharmacy they are important for absorption of fat-soluble vitamins and lipids in the human 
body. They are also part of detergents. 
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Figure 5. A normal phase micelle in aqueous solution (21)
    
Emulsiones (22)
They are mixtures of two or more misciblle liquids. In emulsiones, one liquid termed the 
dispersed phase, is disperesed in the other, termed the continuous phase. The phases are 
described according to phases in milk – water (w), and oil (o). We have several types of 
emulsiones, two basic; o/w miscible in water and w/o miscible in oil and some others; w/w, 
o/o, o/w/o, w/o/w. 
Viscosity  and  color  depend  on  the  size  of  droplets.  Viscosity  is  bigger  with  smaller 
droplets. During storage that gets lower with instability of droplets. The smaller one (under 
0,1μm) are transparent. Particles bigger than 1μm are white.
They  can  also  manifest  several  types  of  breakdowns  –  creaming,  sedimentation, 
flocculation,  phase  inversion,  coalescence,  and  Ostwald  ripering.  Creaming  and 
sedimatation are results of gravitational or centrifugal forces. They are admissible in case 
of easy way to repair during using. Flocculation is a process of aggregation of the droplets 
into larger units. Phase inversion is a process of an exchange between the dispersed phase 
and  the  medium.  It  is  useful  property  in  preparations.  Coalescence  is  the  process  of 
thinning and disruption of the liquid film between the droplets  causing a formation of 
larger droplets. Ostwald ripering is a process of difuse transfer of small droplets in the 
biggers. That causes lower interface tension.
To ensure a stability of emulsiones we can do by using several techniques; an incresing of 
external  phase  viscosity  by  addition  by  e.g.  glycerol,  an  increasing  of  internal  phase 
viscosity, a droplet reducing, an enlargement of surfactant concentration and an increasing 
of internal phase ratio. These all techniques lead to lowering of surface tension or incresing 
viscosity.
The addition of emulsifiers (surfactants) is very important point during preparation. Their 
addition into the phase where are soluble is called English method. Their addition into the 
phase where are not soluble is called continental method. Other methods are a dilution of 
 20
emulsifiers by adding of both phases and in situ preparation.  
There are  stated applications of emulsiones: food industry – mayonnaise,  salas creams, 
deserts; personal care, cosmetic products; pharmaceuticals – an anesthetics o/w emulsiones, 
lipod emulsiones, double and multiple emulsiones; paints.
1. 3. 3 The modification of molecular structure (8)
The  goals  of  modification  of  molecular  structure  can  be  getting  new  molecules  and 
elimination, improvement or change certain characteristics. 
It  is  necessary  to  lower  instability  of  some  drugs.  It  is  done  by  masking  of  reactive 
molecules. This type of modification improves stability in different pH conditions, more 
water-proof and it is useful againts enzyme degradation.
1. 3. 4 Complex formation (8)
Drugs and excipients  formed into complexes  can also improve stability.  Between them 
there  exist  forces  different  nature.  They  can  be  van  der  Waals  forces,  dipole-dipole 
interactions,  hydrogen  bonding,  Coulomb  forces,  and  hydrophobic  interactions.  For 
stabilizations caffaine is often used together with e.g. benzocaine and procaine.
1. 3. 5 Addition of stabilizers (8)
This techniques lead to stabilization mostly againts oxygen, light and moisture. Effect of 
oxygen can be eliminated by using antioxidants. For this purpose it can be used α-tocoferol, 
butylated hydroxyanisole, ascorbic acid and thioglycolic acid. 
Againts light, photodegration and moisture we use special photoprotective and moisture-
proof   films  or  in  some  cases  oxygen  absorbent.  Photoprotective  compounds  are  e.g. 
titanium dioxide, naphthylamine.
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1. 4 Theoretical introduction to the experimental part
1. 4. 1 Chromatographic introduction
Chromatographic  methods  are  widely  used  in  analytical  procedures.  Their  principle  is 
separation  of  mixtures.  They enable  to  measure  both  qualitative  and  quantitative 
information.  
Chromatography (23, 24) uses to separation two phases. The first one is called the mobile 
phase and the second one is stationary phase. There is dissolved the mixture in the mobile 
phase, it also eluates single constituents from mixture and carries them at different speeds. 
The stationary phase has an ability to hold the constituents. There exist interaction between 
these  two  phases,  causing  their  separation.  There  is  forming  repeatedly  the  dynamic 
balance  between the  sorption  of  stationary phase  and   the  desorption  to  mobile  phase 
during the procedure. The speed of eluation depends on how the constituents are held in the 
stationary phase.
Chromatographic  methods  can  divide  into  several  groups.  The  division  can  be  done 
accoding  to  following  characteritics:  physical  state  of  mobile  phase  (gas,  liquid 
chromatography), chromatographic bed shape (column, paper, thin-layer chromatography), 
separation (adsorption, ion exchange, size-exclusion, affinity, distributive chromatography)
1. 4. 2 High Performance Liquid Chromatography
HPLC is one of the most common methods for identification, separation and quantification 
molecules.
It is a form of column chromatography. Its advantages are in simplicity and speed. 
The equipment consists of a pumping system, a chromatographic column, an injector, a 
detector  and a  data  acquisition  system.(25)  The mobile  phase  is  supplied  from one of 
several reservoirs and flows through the column,  normally at  a  constant  rate,  and then 
through the detector. 
The pumping system is capable to inject the solvents under pressure of 300 bars. Nowadays 
pressure systems are more efficient and they can operate with pressure up to 600 bars. The 
injection can be realized manually which can be inaccurate or by an auto-sampler. 
We have several types of stationary phase.  The splitting into these groups is based on 
mechanism  of  separation.  We  use  silica,  alumina  or  porous  graphite  in  normal-phase 
chromatography,  resins  or  polymers  with  acid  or  basic  groups  in  ion-exchange 
chromatography, porous silica or polymers in size-exclusion chromatography, a variety of 
 22
chemically  modified  supports  prepared  from  polymers,  silica  or  porous  graphite  in 
reversed-phase liquid chromatography and finally special chemically modified stationary 
phase, e.g. proteins or peptides, cellulose or amylase derivatives.(25)
Mobile phase has to be clear and free from dissolved gases. For better separation of acid 
and basic compounds we can add a small amount of acids, alkalies, or buffer.
The separation (25) is based on interaction of compounds between stationary and mobile 
phase.  The  mechanism  of  retention  is,  when  we  use  normal  phase  (silica  material), 
adsorption by hydrogen bonds between the polar groups of the stationary phase and of the 
molecule. The molecules are washed in increasing polarity. In case of reversed-phase where 
the silica gel is usually coated with hydrocarbon chains of various lengths, normally used 
C4, C6 or C18 chains, the mechanism of retention is based on absorption by the Van der 
Waals interactions between the lipophilic regions of the molecules and the lipophilic chains 
of stationary phase.  For example, those samples which have stronger connections with the 
mobile phase than with the stationary phase will elute from the column faster. It also means 
they have shorter retention time, while the reverse is also true.
There  are  several  types  of  mobile  phases:  an  isocratic  elution  -  there  is  used  constant 
amount and composition of mobile phase during the measurement, a  gradient elution – 
there is used increasing the strength of the organic solvent.
HPLC  is  very  useful  method  for  identification  molecules  such  as  drug  molecules, 
metabolites, lipids, peptides, etc. in analytical chemistry and biochemistry. 
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2. Experimental part 
This experiment was realized on University of Eastern Finland, Faculty of Pharmacy. It 
was created at  a lab of Deparment of Pharmaceutical Chemistry (DoPCh) but done for 
Department of Pharmaceutical Technology (DoPT) and their scietific project. 
This is one of two diplomas created there. The first part of experiment is common for both 
works, the next parts are differ in used compounds but the procedure is same. 
The  final  processing  was  done on Charles  University,  Faculty of  Pharmacy in  Hradec 
Králové.
My experiment was divided into three parts. 
First part of experiment was focused on optimization of chromatographic conditions. It was 
used 38 active compounds (26) and there were tried various chromatographic conditions 
(various concentrations od mobile phase)  The goal of this part was a determination of 
suitable mobile phase composition for the corresponding group of compounds.
Validation was done as the second step.
In the third last part there were done measurings if the compouds after melt quenching 
degrade or not. Standards and modified samples were compared.
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2. 1 Instruments
Instrument used in the lab of DoPCh (using these instruments was a part of this work)
 HPLC equipment
Merck Hitachi LaChrom
Merck Hitachi Interface D-7000
Merck Hitachi Diode Array Detector L-7455
Merck Hitachi Programmable Autosampler L-7250
 Chromatographic column
HPLC Column Agilent Technologies
Zorbax Eclipse XDB-C18
Rapid Resolution HT 4,6x50mm 1,8-Micron 600 Bar
 Column oven (MetaChem Technologies Inc., California, USA)
 Analytical balance (Mettler Toledo AX205, Mettler Toledo, Greifensee, Switzeland)
 pH meter (Orion 3 Star Benchtop)
Instruments used in a lab of DoPT for a preparation of comperative samples (using these 
instruments was not a part of this work but it was worked with samples modified this way 
in experiment)
 Hot  stage (Linkam  Scientific  Instruments  Ltd,  UK)  of  the  polarizing  light 
microscope (Nikon LV100D, Japan)
 Aluminium pans (Mettler Toledo, Switzerland)
 Analytical balance (Sartorius SE2, Sartorius AG, Germany)
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2. 2 Chemicals
Chemicals  for  preparation  of  the  mobile  phase,  the  buffer  and  the  solvent  of  active 
substances
HPLC methanol: HPLC Gradient Grade 99,8%, J.T.Baker, Deventer, The Netherlands
HPLC acetonitrile: HPLC Gradient Grade 99,9%, VWR Oy, Helsinki, Finland
Ortho-phosphoric acid 85%, Merck, Darmstadt, Germany
10mM solution of sodium hydroxide, FF-Chemicals, Haukipudas, Finland
purified and deionized water, Millipore Milli-Q system, Massachussets, USA
All used compounds:
Diflunisal, Sigma Aldrich, St. Louis, USA
Fenbufen, Sigma Aldrich, St. Louis, USA
Flurbiprofen, Sigma Aldrich, St. Louis, USA
Flutamide, Sigma Aldrich, St. Louis, USA
Ibuprofen, Sigma Aldrich, St. Louis, USA
Ketoprofen, Sigma Aldrich, St. Louis, USA
Mefenamic acid, Sigma Aldrich, St. Louis, USA
Naproxen, Sigma Aldrich, St. Louis, USA
Nimesulide, Sigma Aldrich, St. Louis, USA
Tolfenamic acid, Sigma Aldrich, St. Louis, USA
Acetazolamide, Sigma Aldrich, St. Louis, USA
Acetylsalicylic acid, Sigma Aldrich, St. Louis, USA
Benzocaine, Sigma Aldrich, St. Louis, USA
Captopril, Sigma Aldrich, St. Louis, USA
Chlorpropamide, Sigma Aldrich, St. Louis, USA
Chlorthiazide, Sigma Aldrich, St. Louis, USA
Cimetidine, Sigma Aldrich, St. Louis, USA
Clotrimazole, Sigma Aldrich, St. Louis, USA
Famotidine, Sigma Aldrich, St. Louis, USA
Furosemide, Sigma Aldrich, St. Louis, USA
Nitrofurantoin, Sigma Aldrich, St. Louis, USA
Nizatidine, Sigma Aldrich, St. Louis, USA
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Paracetamol, Sigma Aldrich, St. Louis, USA
Perphenazine, Sigma Aldrich, St. Louis, USA
Piroxicam, Sigma Aldrich, St. Louis, USA
Primidon, Sigma Aldrich, St. Louis, USA
Pyrazinecarboxamid, Sigma Aldrich, St. Louis, USA
Pyridoxine, Sigma Aldrich, St. Louis, USA
Saccharine, Sigma Aldrich, St. Louis, USA
Salicylamide, Sigma Aldrich, St. Louis, USA
Salicylic acid, Sigma Aldrich, St. Louis, USA
Sulfadiazide, Sigma Aldrich, St. Louis, USA
Sulfadimidine, Sigma Aldrich, St. Louis, USA
Sulfamethoxazole, Sigma Aldrich, St. Louis, USA
Sulfamerazine, Sigma Aldrich, St. Louis, USA
Sulfanilamide, Sigma Aldrich, St. Louis, USA
Thiosalicylic acid, Sigma Aldrich, St. Louis, USA
Tolbutamide, Sigma Aldrich, St. Louis, USA
Purity was in a range of 97 and 101%.
¨
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2. 3 Division of all used compounds according to their therapeutic 
applications
We had 38 active  substances  at  the  beginning.  We divided them into  several  different 
groups. The first biggest group was non-steroidal anti-inflammatory drugs (NSAIDs) stated 
in  the  Table  1.  There  are  14  compounds.  The  second  group  was  ATBs  and 
chemotherapeutics also stated  in Table 1. There are 7 compounds. In the Table 2 there were 
mentioned  compounds  belonging  to  the  group  of  antidiabetics,  diuretics,  H2-receptor 
antagonists,  local  anaesthetics,  food  additives,  anticonvulsive  drugs,  antiandrogens, 
antipyretics, antipsychotics, ACEis, antifungal drugs and vitamins. There are stated pKa 
values for every compound.
Table 1. The list of NSAIDs, ATBs and chemotherapeutics
NSAIDs           pKa ATB + chemotherapeutics                pKa
acetylsalicylic acid 3,49 nitrofurantoin 7,20
diflunisal 2,94 pyrazinecarboxamide 13,91
fenbufen 5,60 sulfadiazine 6,50
flurbiprofen 4,14 sulfadimidine 7,75
ibuprofen 5,20 sulfamerazine 8,00
ketoprofen 4,23 sulfamethoxazol 5,81









Table 2. List of other used drugs

















local anesthetic benzocaine 2,51
food additive saccharine 1,31





antifungal drug clotrimazole 6,12
vitamine pyridoxine 8,37
* xx – we did not find the value
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2. 4 List and characterisation of chosen compounds used for validation 
and next comparing
There are stated some characteristics such as pKa value, molecular weight (Mr) and melting 
temperature (TM) in ºC in Table 3. It also contains formulas of single compounds.
Table 3. Characterization of the compounds
Compound Formula
Diflunisal pKa = 2,94±0,1
Mr = 250,20
TM = 212,29±0,26
Fenbufen pKa = 4,55±0,2
Mr = 254,28
TM = 185,77±0,15











Ketoprofen pKa = 4,23±0,1
Mr = 254,28
TM = 94,60±0,29
Mefenamic acid pKa = 3,73±0,4
Mr = 241,29
TM= 230,32±0,08
Naproxen pKa = 4,84±0,3
Mr = 230,26
TM = 155,33±0,08
Nimesulide pKa = 5,93±0,1
Mr = 308,31
TM = 148,64±0,05





2. 5  The Preparations and HLPC Measuring
2. 5. 1 Preparation of mobile phase
The mobile  phase  was prepared  by mixing ACN 90% and 50mM phosphate  buffer  in 
various ratios (concrete composition is stated in Table 4 in chapter 6. 1 Optimization of 
chromatographic method). It was degassed by helium about 5 minutes.
ACN 90% contained 90 volumes of acetonitrile and 10 volumes of water. 
The buffer consisted 3,0 ml of 85% ortho-phosphoric acid added to 1000 ml water. It was 
finally adjusted to pH 2,1 with 10M solution of sodium hydroxide and filtered with 0,45 
μm membrane (Durapore) and degassed with helium for about 5 minutes.
2. 5. 2 Preparation of samples for HPLC measuring
It was prepared standard stock solution at the beginning. It was dissolved 25 mg of the 
standard  substance  in  methanol  and  diluted  to  100  ml  with  the  same  solvent.  The 
concentration of the stock solution was 0,25 mg/ml.
For samples it was added 0,8 ml of the stock solution to 9,2 ml of the 50mM phosphate 
buffer pH 2,1. In case of acidic labile substances such as tolfenamic acid and mefenamic 
acid it was used water instead of the buffer. The final concentration of the sample was 0,02 
mg/ml.
For  validation  there  were  prepared  two  sets  of  stock  solutions.  Set  No.  1  was  for 
determination of precision, accuracy, linearity and stability and it was used for three days. 
Set No. 2 was freshly prepared after three days for comparing of stability. 
2. 5. 3 Storage
The mobile phase and the buffer were storing in the room temperature, the stock solutions 
in refrigerator in 4°C and the samples were prepared before use.
2. 5. 4 Melt quenching (using this technique was not a part of this work but it was worked 
with samples modified this way in experiment)
The amorphous samples were heated from room temperature to 15°C above the melting 
point, and held there for 1 minute. Then they were cooled down as the next step to room 
temperature. The samples were analysed in sealed 40 µl aluminium pans with a pierced lid. 
The weight of amorphous compounds on DSC pans was counted in the certain way to be 
comparable to the final concentration of standards in glass vial.
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The  sample  was  put  in  a  20ml  volumetric  flask  and  dissolved  in  methanol.  The 
concentration of these stock solutions was about 0,25 mg/ml. Next step was done in the 
same way as non adjusted samples. 
Stock solution concentrations of standards and modified samples are stated in Table 16 in 
part 2. 6. 3 Comparing of standards and modified amorphous samples.
2. 5. 5 HPLC Measuring
A Hitachi LaChrom apparatus consisted a L-7100 pump with programmable autosampler, a 
diode array detector and a MetaTherm column oven. It was under the control of D-7000 
HPLC System Manager software.
For measurements it was used a reversed-phase C18,50 x 4,6 mm, 1,8 μm particle size 
column. Column oven was operated at 40°C. Detection of UV absorbance was monitored at 
214, 222, 228, 254 nm. The injection volume was 5 μl. Total running time was 6 min. 
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3. Reasults and discussion
The main target of this experiment was to develop right method for several compounds to 
measure their stability and concetration if they after heating and cooling down degradate. 
Every  standard  coumpound  was  measured  individually  to  gain  pure  spectrum with  no 
disturbing peaks.  The goal was not identify the possible degradents. 
3. 1 Optimization of chromatographic method
They  were  determinated  several  conditions  for  choosing  right  method.  It  was  also 
necessary to gain spectra and download them to the library of HPLC equipment for final 
comparing of stability. These compounds are listed in the part  Chemicals.
All coumpounds have different pKa values, structure, molecular weight and UV spectra. 
Because all compounds are ionic so buffer had to be used. 
Chromatographic conditions
Column: a reversed-phase C18, 50 x 4,6 mm, 1,8µm particle size.
Mobile phase: Solvent A: ACN 90%
                        Solvent B: 50mM phosphate buffer pH 2,1
Temperature: 40°C
Flow rate: 1ml/ml
Injection volume: 5µl (c=0,02mg/ml)
Running time: 10 minutes
For getting speed of eluation there were done several experiments with different ratios of 
ACN 90% and the buffer. These ratios are stated in Table 4. 1st method was done with all  
compounds  to  get  spectra  and  maximum absorbance  wavelengths.  First  three  methods 
served as separation method to find their properties in these ratios. Due to measured results 
of three first method, 5 others were tested specifically for only several compounds to get 
the best ratio.      
Selective conditions
Separation time (Rt running time): 5 – 10 minutes
Resolution (k capacity factor):  1,0 – 10,0
Peak height: large S/N ratio
Pressure: less than 150 Bar
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 Table 4. Ratio list of ACN and buffer
Contents
ACN 90% (ml) buffer pH 2,1 (ml)
1st method 65 35
2nd method 50 50
3rd method 30 70
4th method 60 40
5th method 45 55
6th method 57 43
7th method 40 60
8th method 35 65
      
All compounds were dissolved in methanol. Concentration of stock solutions were 0,25 
mg/ml. pKa range of used compounds was wide. It was not possible to get one method for 
all.  For  separation  was  used  a  reversed-phase  column  and  isocratic  eluation.  It  was 
important to find right ratio of mobile phase and the buffer to have capacity factors in set 
interval.
All  compounds  were  measured  by  a  diode-array  detector  and  there  were  monitored 
multiple wavelengths.
In following Table 5 there are stated all compounds with measured Rt.
Table 5. List of Rt all compounds
Rt (min)
Compounds 1st 2nd 3rd 4th 5th 6th 7th 8th 
Acetazolamide 0,49 0,52 0,62 X X X X X
Acetylsalicylic acid 0,59 0,71 1,89 X X 4,49 0,90 1,07
Benzocaine 0,73 1,03 2,53 X X X 1,47 1,88
Captopril 0,53 0,59 0,87 X X X X X
Chlorpropamide 0,77 1,25 5,39 X X X 2,24 1,53
Chlorthiazide 0,49 0,54 0,70 X X X X X
Cimetidine 0,43 0,43 0,47 X X X X X
Clotrimazole 0,65 0,98 X X X X 2,08 3,77
Diflunisal 1,11 2,73 X 1,39 6,29 1,71 X X
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Rt (min)
Compounds 1st 2nd 3rd 4th 5th 6th 7th 8th 
Famotidine 0,43 0,43 0,47 X X X X X
Fenbufen 0,95 1,89 X 1,09 4,09 1,30 X X
Flurbiprofen 1,26 3,11 X 1,58 6,11 1,95 X X
Flutamide 1,38 3,50 X 1,75 6,52 2,18 X X
Furosemide 0,60 0,88 3,44 X 1,77 X 1,45 2,14
Ibuprofen 1,67 4,43 X 2,15 7,36 2,65 X X
Ketoprofen 0,89 1,65 X 1,05 2,84 1,19 3,51 5,92
Mefenamic acid 2,17 6,54 X 3,01 10,00 3,73 X X
Naproxen 0,92 1,73 X 1,08 2,78 1,23 3,65 6,16
Nimesulide 1,10 2,53 X X X 1,67 X X
Nitrofurantoin 0,53 0,60 0,98 X X X X X
Nizatidine 0,43 0,43 0,46 X X X X X
Paracetamol 0,50 0,31 0,59 X X X X X
Perphenazine 0,53 0,65 2,96 X X X 1,00 1,53
Piroxicam 0,86 1,29 4,17 X X X 2,04 2,78
Primidon 0,51 0,59 0,83 X X X X X
Pyrazincarboxamide 0,48 0,49 X X X X X X
Pyridoxin 0,43 0,43 0,45 X X X X X
Saccharin 0,47 0,51 0,60 X X X X X
Salicylamide 0,57 0,65 1,03 X X X X X
Salicylic acid 0,63 0,84 1,35 X 1,41 X 1,15 1,45
Sulfadiazine 0,51 0,55 0,71 X X X X X
Sulfadimidine 0,55 0,62 0,89 X X X X X
Sulfamethoxazole 0,57 0,71 1,39 X X X 0,91 1,11
Sulfamerazine 0,53 0,59 0,79 X X X X X
Sulfanilamide 0,49 0,52 X X X X X X
Thiosalicylic acid 0,37 0,89 2,11 0,71 1,43 X 1,25 X
Tolbutamide 0,85 1,50 7,86 0,98 2,23 X 2,95 4,65
Tolfenamic acid 2,50 8,19 X 0,71 X 4,49 X X
X – it was not measured
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Based on the measured values of Rt (Table 5) and the conditions mentioned above as the 
best method for my next work was chosen the 6th one with ratio of ACN 90% and the 
buffer 57:43. This method was suitable for ten following substances – diflunisal, fenbufen, 
flurbiprofen, flutamide, ibuprofen, ketoprofen, mefenamic acid, naproxen, nimesulide and 
tolfenamic acid.  All these compounds except flutamide are NSAIDs with pKa around 3 – 
5. Flutamide is antiandrogen with pKa 13. We could not explain how this compound would 
be within set conditions.
In following Table 6 there are stated numbers of suitable compounds for each method. 
Althought 5th method has the biggest number the Rt of compounds in interval they are too 
big. From technical reason 6th method was chosen with smaller number of compounds. 
8th method was chosen for the second thesis. 
 
Table 6. Number of suitable compounds for each method  










3. 2 Validation process
Validation was designed and performed according to ICH Harmonised Tripartite Guideline, 
Validation  of  Analytical  Procedures:  Text  and  Methodology  Q2(R1).  (27)  During  the 
experiment  it  was  used  the  assay  as  a  type  of  analytical  procedure.  Based  on  this 
methodology  accuracy,  precision  –  repeatability,  intermediate  precision,  specificity, 
linearity and range were done. Detection limit and quantitation limit were not assessed they 
are not normally evaluated  for this type of experiment. Also robustness and reproducibility 
were not assessed because it  was not necessary to transfer, repeat and verify following 
results in another laboratory. It was performed system suitability test before measurings. 
.
3. 2. 1 Specificity
It  is defined as the ability to measure accurately the concentration of an analyte in the 
presence of all other sample materials. (28) 
There  were  formulated  some  acceptance  criteria.  The  first  one  was  capacity  factor  k 
between 1 and 10. The second one was no disturbing peaks at retention time of analyte. The 
third one was peak pure according peak purity test and similarity of spectrum was over 
95% compared to the library spectrum. They are stated in Table 7. 
Results were measured in maximum absorbance wavelenghts. They are also stated in the 
following Table 7.
Table 7. List of capacity factors and purity of single compounds
Rt (min) k purity Wavelenght(nm) 
Diflunisal 1,50 2,2 1,0000 228
Fenbufen 1,25 1,7 0,9998 214
Flurbiprofen 1,85 2,9 0,9997 222
Flutamide 2,12 3,5 1,0000 228
Ibuprofen 2,58 4,5 1,0000 214
Ketoprofen 1,17 1,5 0,9999 222
Mefenamic acid 3,59 6,6 1,0000 222
Naproxen 1,21 1,6 0,9997 228
Nimesulide 1,55 2,3 1,0000 214
Tolfenamic acid 4,29 8,1 1,0000 222
Void volume 0,47
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3. 2. 2 Linearity
It  is  a  measure  of  how  well  a  calibration  plot  of  response  versus concentration 
approximates a straight line. (28)
For measurements there were prepared samples with 25, 50, 75, 100 and 125% of the target 
concentrations (0,02 mg/ml). The stock solutions were used for preparing corresponding 
dilutions stated in Table 8. It was used 10ml volumetric flask for mixing the stock solution 
with buffer or water.
Table 8. The ratios between stock solution and the buffer in the certain concentrations
  percent concentration (mg/ml) ml of stock solution ml of buffer/water
25 0,005 0,2 9,8
50 0,010 0,4 9,6
75 0,015 0,6 9,4
100 0,020 0,8 9,2
125 0,025 1,0 9,0
This procedure was repeated three times. 
Linearity was evaluated by visual inspection of a plot of signals as a function of analyte  
concentration  or  content.  There  should  be a  linear  relationship  in  an  ideal  situation 
expressed by a straight line. Test results were evaluated by calculating of a regression line 
by the method of least squares. There were also calculated correlation factor; value above 
0,997 was accepted, y-cutting (intercept)  ± 2% from 100% sample area, response factor 
less than ± 2,5 % from 100% and finally slope of the regression line and residual sum of 
squares stated in Tables 9 and 10. 
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Table 9. List of measured and counted y-intercepts, slope of regressions, border values 
(probability 95%), correlation coefficient and y-cutting
TDiflunisal Coefficients Lower 95% Upper 95%
y-intercept 17607,9 -138225 173441
slope of regression 951,5 -899 2802
correlation coefficient 0,0876
y-cutting (%) 7,70
Fenbufen Coefficients Lower 95% Upper 95%
y-intercept 28296,2 7794 48799
slope of regression 633,9 393 875
correlation coefficient 0,7126
y-cutting (%) 32,50
Flurbiprofen Coefficients Lower 95% Upper 95%
y-intercept 8533,5 6366 10701
slope of regression 476,9 451 502
correlation coefficient 1,0000
y-cutting (%) 14,20
Flutamide Coefficients Lower 95% Upper 95%
y-intercept 15645,9 14045 17247
slope of regression 744,8 726 754
correlation coefficient 1,0000
y-cutting (%) 17,20
Ibuprofen Coefficients Lower 95% Upper 95%
y-intercept 13338,2 10605 16071
slope of regression 591,7 559 624
correlation coefficient 1,0000
y-cutting (%) 17,90
Ketoprofen Coefficients Lower 95% Upper 95%
y-intercept 13965 12210 15720




Mefenamic acid Coefficients Lower 95% Upper 95%
y-intercept 58554,2 9132 107977
slope of regression 1015,8 435 1597
correlation coefficient 0,5233
y-cutting (%) 39,10
Naproxen Coefficients Lower 95% Upper 95%
y-intercept 106022,5 93392 118653
slope of regression 5259,6 5111 5408
correlation coefficient 1,0000
y-cutting (%) 16,50
Nimesulide Coefficients Lower 95% Upper 95%
y-intercept 43878,4 23956 63801
slope of regression 456,6 218 695
correlation coefficient 1,0000
y-cutting (%) 40,10
Tolfenamic acid Coefficients Lower 95% Upper 95%
y-intercept 49008,7 32557 65460
slope of regression 1327,9 1129 1527
correlation coefficient 1,0000
y-cutting (%) 25,40
Generally speaking based on these results we can say this measuring did not go well. 
Border  values  are  too  wide.  Correlation  coefficients  of  diflunisal,  fenbufen  and 
mefenamic acid are too low but that does not mean there is no linear relationship. Y-
cutting does not comply with stated interval in all cases.  
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Diflunisal 25,39 155,9 Ketoprofen 24,97 66,0
50,78 220,0 49,94 84,3
76,17 226,1 74,91 91,3
101,56 100,0 99,88 100,0
126,95 412,6 124,85 100,0
Fenfufen 25,63 54,2 Mefenamic acid 25,65 42,0
51,26 72,3 51,30 56,9
76,89 72,9 76,95 109,8
102,52 100,0 102,60 100,0
128,15 100,8 128,25 89,0
Flurbiprofen 25,50 72,2 Naproxen 25,59 65,9
51,00 92,1 51,18 86,3
76,50 101,9 76,77 95,2
102,00 100,0 102,36 100,0
128,15 109,8 127,95 102,9
Flutamide 25,40 65,6 Nimesulide 25,20 60,0
50,80 85,1 50,40 78,1
76,20 94,0 75,60 98,1
102,00 100,0 100,80 100,0
127,00 102,8 126,00 164,0
Ibuprofen 25,23 67,6 Tolfenamic acid 24,91 72,2
50,46 87,1 49,82 92,1
75,69 94,7 74,73 101,9
100,92 100,0 99,64 100,0
126,92 108,0 124,55 109,8
The most of gained values are not also inside the interval. In 25% and 50% concentration it 
is not so important it was not measured with these low concentrations further but deviations 
from  set  2,5%  are  too  high.  In  higher  concentrations  they  are  mostly  closer  except 
diflunisal that is completely out of interval.
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3. 2. 3 Range
It  is  the lower and upper  concentrations  for  which the analytical  method has adequate 
accuracy, precision, and linearity. (28)
In this case the range was between 25 and 125%.
3. 2. 4 Accuracy
It is the closeness of the measured value to the true value. (28)
It was assessed by using 9 different determinations over 3 concentration levels covering the 
specified  range,  for  this  case  that  was  3 replicates  for  every concentration.  Values  are 
averaged. Accuracy was calculated as a ratio of concentration measured and concentration 









Diflunisal 76,17 15,24 9.83 64,5
101,56 20,32 44,40 218,5
126,95 25,39 10,84 42,7
Fenbufen 76,89 15,27 19,23 125,9
102,52 20,45 18,51 90,5
128,15 25,63 25,14 98,1
Flurbiprofen 76,50 15,40 15,02 97,5
102,00 20,45 21,60 105,6
127,50 25,50 25,01 98,1
Flutamide 76,20 15,24 15,27 100,2
101,60 20,32 20,20 99,4
127,00 25,40 25,48 100,3
Ibuprofen 75,69 15,30 15,65 102,3
100,92 20,18 20,72 102,7
126,15 25,23 24,70 97,9
Ketoprofen 74,91 14,99 15,29 102,0
99,88 19,98 19,44 97,3









Mefenamic acid 76,95 15,29 8,58 56,1
102,60 20,47 17,93 87,6
128,25 25,65 29,75 116,6
Naproxen 76,77 15,25 15,14 99,3
102,36 20,57 20,53 99,8
127,95 25.59 25,69 100,4
Nimesulide 75,60 15,12 10,4 114,2
100,80 20,16 21,55 142,5
126,00 15,12 17,34 68,8
Tolfenamic acid 74,73 14,95 0,58 3,9
99,64 19,93 0,78 3,9
124,55 24,91 0,58 3,4
Accuracy of flurbiprofen, flutamide, ibuprofen, ketoprofen and naproxen goes to 100% in 
all  three  tested  concentrations.  Fenbufen  has  bigger  deviation.  Results  for  diflunisal, 
nimesulide and tolfenamic acid are very inaccurate.
3. 2. 5 Precision
It is the degree of agreement among individual test results when the procedure is applied 
repeatedly to multiple samplings of a homogeneous sample. (28) It is divided into three 
groups; repeatability – the precision under same operating conditions over a short period of 
time,  intermediate  precision  –  the  agreement  of  complete  measurements  in  the  same 
laboratory during different days, and  reproducibility – the precision between laboratories.
For our purpose there were used just first two types. 
Every sample was measured three following days in six replicates in 100% (0,02 mg/ml) 
concentration. 
Precision  was  expressed  by  using  relative  standard  deviation  (RSD)  and  precision 
confidence interval (CI).  RSD under 10% was accepted. Table 12 is for set No. 1, Table for 
13 is for set No. 2
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Table 12. Precision, set No. 1
Compound SD of area RSD of area (%) Area CI
Diflunisal 48907 41,99 116478 ± 513132
Fenbufen 24419 16,62 146922 ±25620
Flurbiprofen 1025 1,68 61054 ±1075
Flutamide 757 0,83 91610 ±794
Ibuprofen 1863 2,49 74783 ±1956
Ketorpofen 737 0,87 84906 ±773
Mefenamic acid 11709 9,92 118083 ±12285
Naproxen 8331 1,28 649076 ±8741
Nimesulide 29310 25,97 112883 ±30752
Tolfenamic acid 6524 4,74 37510 ±66845
Table 13. Precision, set No. 2
Compound SD of area RSD of area (%) Area CI
Diflunisal 108990 79,34 137371 ±114352
Fenbufen 5414 2,96 182594 ±5680
Flurbiprofen 1161 1,99 58412 ±1218
Flutamide 1313 1,56 87584 ±1378
Ibuprofen 1581 2,04 77522 ±1659
Ketoprofen 512 0,62 83526 ±537
Mefenamic acid 11601 5,04 230457 ±12172
Naproxen 9776 1,60 609703 ±10257
Nimesulide 4756 4,42 107726 ±4990
Tolfenamic acid 21434 9,81 218492 ±22489
Results from set No. 2 are better. All compounds except diflunisal fulfil criterion. In case of 
set No. 1 there 3 compounds with very bad results and mefenamic acid has border values.  
3. 2. 6 Stability
For stability studies there were compared results from the second day of precision and the 
third day of precision with freshly prepared stock solution. If stability of the solution was 
low, the next analyses were performed during one day. The results are stated in Table 14.
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Table 14. Stability of compounds during 3 days
Stability (%)
Compound 1st day 2nd day 3rd day
Diflunisal 188,50 184,1 204,3
Fenbufen 80,46 16,2 7,9
Flurbiprofen 104,52 102,7 102,5
Flutamide 104,60 102,7 105,5
Ibuprofen 96,47 96,0 99,0
Ketoprofen 101,66 99,9 104,1
Mefenamic acid 51,24 36,1 20,8
Naproxen 106,46 78,4 70,0
Nimesulide 104,79 30,4 25,3
Tolfenamic acid 62,11 46,9 41,3
Flurbiprofen, flutamide, ibuprofen, ketoprofen are stable compounds. Naproxen is unstable. 
Its solutions must be prepared freshly before experiment. Results of diflunisal, fenbufen, 
nimesulide, mefenamic acid and tolfenamic acid are ambiguous. They cannot be used as a 
relevant.  Generally  tolfenamic  and  mefenamic  acids  are  unstable  in  acidic  solutions. 
Solutions for next experiment were prepared right before measuring.
3. 2. 7 System suitability test
Every day before measurements there was SST. It was done by using ketoprofen as a stable 
substance with six replicates. It was calculated RSD of Rt and the area under the peak. The 
criterion was less than 1%. RSD was in every cases under 1%.
3. 2. 8 Re-measuring
Based on previous unsatisfactory results there was a discussion. Almost every results of 
diflunisal, mefenamic acid, naproxen, nimesulide and tolfenamic were out of interval or 
nonsense. After that we found that mistake was in using still same plastic pipettes. They 
could  not  take  exactly  same volume for  whole  experiment.  It  was  designed one  other 
measuring for confirmation of this hypothesis.  It was used only glass pipette. 
It was used lineary test again with ketoprofen as the most stable compound. 
It was prepared 1 basic stock solution by dissolving approximately 25 mg of ketoprofen in 
methanol  and  diluting  to  100  ml  with  the  same  solvent  (Table  15a).  From this  stock 
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solution it was prepared Dilution I. 10 ml of stock solution was taken and put into 50ml 
volumetric  flask  and  solved  in  mobil  phase.  The  concentration  of  this  dilution  was 
approximately 0.05 mg/ml (Table 15b). From this dilution there were prepared 5 others 
dilutions (standard = STD) (Table 15c). From STD 2 there were prepared 3 other dilutions 
(Table 15d). Every standard was measured in three replicates. Exact values are stated in the 
following tables. 
Table 15 a) Preparing of stock solution
Ketoprofen Weight (mg) Concentration (mg/ml) Calculated concetration 
(mg/ml)
Stock solution 24,98 0,2500 0,2498
Table 15 b) Preparing of Dilution I








Dilution I 10,00 50,00 0,0500 0,0500
Table 15 c) Dilutions from Dilution I













STD1 1,00 10,00 0,0050 0,004996 24,98
STD2 2,00 10,00 0,0100 0,009992 49,96
STD3 3,00 10,00 0,0150 0,014988 74,88
STD4 4,00 10,00 0,0200 0,019984 99,92
STD5 5,00 10,00 0,0250 0,024980 124,90
Table 15 d) Dilutions from STD2













STD6 1,00 10,00 0,0010 0,0009921 4,97
STD7 2,00 10,00 0,0020 0,0019984 9,99
STD8 3,00 10,00 0,0030 0,0029976 14,99
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Following graph shows how exact was measuring. Calculated concentrations and measured 
concentrations are almost identical. Y-intercept is getting closer to zero.
 
Graph 1. Repeated linearity test with ketoprofen
According these results we can say that the mistake was really in using plastic pipettes. 
During third part there was used only glass pipette and solutions were prepared right before 
measuring to prevent another inaccuracy. 
Although  results  from validation  were  very  inaccurate  we  decided  to  continue  in  our 
experiment and not to repeat it. Final results are not  impacted.
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3. 3 Comparing of standards and modified samples
In the last part of experiment we studied stability of compounds after heating and cooling if 
they degraded or not. We measured again freshly prepared standard solutions of 10 chosen 
compounds and modified amorphous samples prepared by laboratory of Department  of 
Pharmaceutical  Technology.  Weight  was  calculated  to  be  comparable  to  each  other.  In 
Table 16 there are exact concentrations of stock solutions.
Table 16. Concentrations of standards and modifies samples in stock solutions








Mefenamic acid 0,2015 0,2039
Naproxen 0,2930 0,2949
Nimesulide 0,2684 0,2664
Tolfenamic acid 0,2307 0,2254
  
In the following Table 17 there are results for every single compound. The most important 
factors for comparing are purity,  should be  >0,9997, and stability  <5%. RSD  <2,5% is 
accepted.
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Table 17. Comparing standards and samples after melt-quenching
NSAIDs
compounds              Rt conc (mg/ml) Stability (%)          Purity
diflunisal 1,67 0,0278 111,3 0,9998
RSD(%) 0,35 0,87 0,87 0
fenbufen 1,17 0,0257 93,3 0,9993
RSD(%) 0,00 0,3 0,3 0,01
flurbiprofen 1,94 0,0279 104,4 0,9997
RSD(%) 0,52 1,16 1,16 0,01
ibuprofen 2,70 0,0275 102,2 1,0000
RSD(%) 0,43 0,69 0,69 0
ketoprofen 1,13 0,0291 102,1 0,9996
RSD(%) 2,85 0,64 0,64 0,01
mefenamic acid 3,71 0,0199 97,6 0,9999
RSD(%) 0,27 0,81 0,81 0
naproxen 1,18 0,0297 100,7 0,9998
RSD(%) 0,49 0,8 0,8 0
nimesulide 1,65 0,0278 92,9 0,9997
RSD(%) 0,35 0,98 0,98 0,01
tolfenamic acid 4,47 0,0229 101,6 0,9999
RSD(%) 0,59 4,39 4,39 0
antiandrogen
flutamide 2,07 0,0273 95,9 0,9997
RSD(%) 0,28 1,17 1,17 0
Purity of compounds is high in every cases. Diflunisal, fenbufen and nimesulide are outside 
of the interval but not so much. 
For  better  comparing  there  are  shown  below  representative  chromatograms  of  every 
standards and amorphous samples
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Figure 6. Representative chromatograms of diflunisal std (A) and diflunisal sample 
(B) with Rt and area 
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A: Rt = 1,67, Area = 103916 
B: Rt = 1,67, Area = 116204
Figure 7. Representative chromatograms of fenbufen std (C) and fenbufen sample (D) 
with Rt and area
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D: Rt = 1,17, Area = 158947
C: Rt = 1,18, Area = 169965
Figure 8. Representative chromatograms of flurbiprofen std (E), flurbiprofen sample 
(F) with Rt and area
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E: Rt = 1,94, Area = 48025
F: Rt = 1,94, Area = 50792
Figure 9. Representative chromatograms of flutamide std (G) and flutamide sample 
(H) with Rt and area
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G: Rt = 2,07, Area = 86375
H: Rt = 2,07, Area = 82463
Figure 10. Representative chromatograms of ibuprofen std (I) and ibuprofen sample 
(J) with Rt and area
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I: Rt = 2,68, Area = 72128
J: Rt = 2,70, Area  = 73410
Figure  11.  Representative  chromatograms  of  ketoprofen  std  (K)  and  ketoprofen 
sample (L) with Rt and area
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K: Rt = 1,17, Area = 80208
L: Rt = 1,13, Area = 81895
Figure 12. Representative chromatograms of mefenamic acid std (M) and mefenamic 
acid (N) with Rt and area
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M: Rt = 3,71, Area = 168769
N: Rt = 3,71, Area = 166466
Figure 13. Representative chromatograms of naproxen std (O) and naproxen sample 
(P) with Rt and area
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O: Rt = 1,18, Area = 169965
P: Rt = 1,18, Area = 594308
Figure  14.  Representative  chromatograms  of  nimesulide  std  (Q)  and  nimesulide 
sample (R) with Rt and area
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Q: Rt = 1,65, Area = 105481
R: Rt = 1,65, Area = 109431
Figure 15. Representative chromatograms of tolfenamic acid std (S) and tolfenamic 
sample (T) with Rt and area
  
Previous results shows that all tested compounds are thermal stable.
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S: Rt = 4,45, Area  = 199065
T: Rt = 4,47, Area = 179347
4. Conclusion
The main aim of this work was to find, validate an useful HPLC method for group of 
compounds to measure their potential thermal instability.
This work is divided into three parts from this reason.
It the first part it was worked with wide group of 38 active substances. It was necessary to 
gain spectra and download them to the library of HPLC equipment for final comparing of  
stability.  These  compounds  are  listed  in  the  chapter  Chemicals,  and  also  in  one  other 
chapter there are divided according to their therapeutic application. All compounds have 
variable pKa values, structures, molecular weight, and UV spectra. We measured Rt of all. 
Rt values depend on composition of mobile phase. Due to this we used 8 different mobile 
phases with variable ratios of ACN and the buffer. This is stated in Table 4. Rt values are in 
Table  5.  Based  on  these  results  we  decided  to  continue  with  the  group  of  10  active 
substances  –  diflunisal,  fenbufen,  flurbiprofen,  flutamide,  ibuprofen,  ketoprofen, 
mefenamic acid,  naproxen,  nimesulide,  and tolfenamic acid.  The suitable  ratio  of ACN 
90% and 50mM phosphate buffer pH 2,1 was 57: 43. All compounds except flutamide are 
NSAIDs with pKa around 4, flutamide has it much more higher around 13. We could not 
explain that. 
In the second part we validated this chosen method. It was worked only with 10 selective 
compounds. Their characteristics are stated in chapter 2. 4. Results did not end well. During 
the validation process it was made one systematic mistake. It was used plastic pipettes all 
the time without any changes instead of glass pipettes. All process was done this way. It 
caused  incorrect  and  inaccurate  measurements.  This  mistake  was  proved  by  another 
experiment  before  next  measurements.  The  results  are  stated  in  chapter  Re-measuring. 
Another  possible  explanation  for  inaccuracy  of  several  drugs  can  be  in  their  labile 
characteristic in acidic environment. These problems were eliminated by using strictly glass 
pipettes during lab work and sample preparation right before use. 
In the third part the comparing Rt and purity proved that at least in nine substances there is 
no degradation after heating the sample during an amorphous state preparation.  There are 
no extra peaks, no different Rt and purity is still high. In two cases there are unexpected 
small peaks. There is the small peak in time 1,23 in mefenamic acid std but there is no peak 
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in mefenamic acid sample. This could be explaned by contamination of sample. Also the 
small peak in time 3,75 appeared in fenbufen sample. Together with lower stability and 
purity it could indicate small degradation. Next explanation is contamination. This peak 
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